These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23742030)

  • 21. The Impact of Bilastine on Symptoms of Allergic Rhinitis and Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Abdelshafy AM; Abdallah SY; Hassan AF; Mohamed HA; Kamal NM; Ali ST; Abdelhaleem IA
    Am J Rhinol Allergy; 2022 Sep; 36(5):684-694. PubMed ID: 35593100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mizolastine in primary acquired cold urticaria.
    Dubertret L; Pecquet C; Murrieta-Aguttes M; Leynadier F
    J Am Acad Dermatol; 2003 Apr; 48(4):578-83. PubMed ID: 12664022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1) -antihistamine dose escalation.
    Magerl M; Pisarevskaja D; Staubach P; Martus P; Church MK; Maurer M
    Br J Dermatol; 2012 May; 166(5):1095-9. PubMed ID: 22242678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments.
    García-Gea C; Martínez-Colomer J; Antonijoan RM; Valiente R; Barbanoj MJ
    J Clin Psychopharmacol; 2008 Dec; 28(6):675-85. PubMed ID: 19011437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients.
    Demonte A; Guanti MB; Liberati S; Biffi A; Fernando F; Fainello M; Pepe P
    Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):820-828. PubMed ID: 29461615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
    Bachert C; Kuna P; Sanquer F; Ivan P; Dimitrov V; Gorina MM; van de Heyning P; Loureiro A;
    Allergy; 2009 Jan; 64(1):158-65. PubMed ID: 19132976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study.
    Serra E; Campo C; Novák Z; Majorek-Olechowska B; Pulka G; García-Bea A; Labeaga L
    J Dermatolog Treat; 2020 May; 31(3):270-278. PubMed ID: 30835579
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
    Grekowitz E; Metz M; Altrichter S; Bauer A; Brockow K; Heine G; Lionnet L; Saday KK; Hultsch T; Søerensen OE; Maurer M
    Br J Dermatol; 2024 May; 190(6):825-835. PubMed ID: 38308655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bilastine: in allergic rhinitis and urticaria.
    Carter NJ
    Drugs; 2012 Jun; 72(9):1257-69. PubMed ID: 22686617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study.
    Kuna P; Bachert C; Nowacki Z; van Cauwenberge P; Agache I; Fouquert L; Roger A; Sologuren A; Valiente R;
    Clin Exp Allergy; 2009 Sep; 39(9):1338-47. PubMed ID: 19438584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study.
    Okubo K; Gotoh M; Asako M; Nomura Y; Togawa M; Saito A; Honda T; Ohashi Y
    Allergol Int; 2017 Jan; 66(1):97-105. PubMed ID: 27421817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioequivalence Evaluation of Three Pediatric Oral Formulations of Bilastine in Healthy Subjects: Results from a Randomized, Open Label, Crossover Study.
    Sádaba B; Azanza JR; García-Bea A; Labeaga L; Campo C; Valiente R
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):265-272. PubMed ID: 31820304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria.
    Sologuren A; Viñas R; Cordón E; Riesgo SE; Del Mar Forés M; Senán MR; Fernández S; Labeaga L; Ruiz-Miján M
    Allergy Asthma Proc; 2018 Jul; 39(4):299-304. PubMed ID: 29559031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral availability of bilastine.
    Sádaba B; Gómez-Guiu A; Azanza JR; Ortega I; Valiente R
    Clin Drug Investig; 2013 May; 33(5):375-81. PubMed ID: 23529786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bilastine: a lifetime companion for the treatment of allergies.
    Church MK; Tiongco-Recto M; Ridolo E; Novák Z
    Curr Med Res Opin; 2020 Mar; 36(3):445-454. PubMed ID: 31612732
    [No Abstract]   [Full Text] [Related]  

  • 36. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.
    Farré M; Pérez-Mañá C; Papaseit E; Menoyo E; Pérez M; Martin S; Bullich S; Rojas S; Herance JR; Trampal C; Labeaga L; Valiente R
    Br J Clin Pharmacol; 2014 Nov; 78(5):970-80. PubMed ID: 24833043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of the Efficacy of Antihistamines in Chronic Spontaneous Urticaria Based on Initial Suppression of the Histamine- Induced Wheal.
    Sánchez J; Zakzuk J; Cardona R
    J Investig Allergol Clin Immunol; 2016; 26(3):177-84. PubMed ID: 27326985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.
    Grant JA; Riethuisen JM; Moulaert B; DeVos C
    Ann Allergy Asthma Immunol; 2002 Feb; 88(2):190-7. PubMed ID: 11868924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Model-informed pediatric development applied to bilastine: Analysis of the clinical PK data and confirmation of the dose selected for the target population.
    Vozmediano V; Lukas JC; Encinas E; Schmidt S; Sologuren A; Valiente R; Labeaga L; Campo C; Rodriguez M
    Eur J Pharm Sci; 2019 Feb; 128():180-192. PubMed ID: 30468868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modern approaches to the diagnosis and treatment of cold contact urticaria.
    Krause K; Zuberbier T; Maurer M
    Curr Allergy Asthma Rep; 2010 Jul; 10(4):243-9. PubMed ID: 20446123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.